(Q38266338)

1 September 2017

1 reference

title

Current status of antibody therapy in ALL. (English)

1 reference

1 September 2017

Jing Ai

1

1 reference

1 September 2017

Anjali Advani

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

10 November 2014

1 reference

British Journal of Haematology

1 September 2017

published in

1 reference

1 September 2017

volume

168

1 reference

1 September 2017

issue

4

1 reference

1 September 2017

page(s)

471-480

1 reference

New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors

1 September 2017

cites work

1 reference

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

21 January 2018

1 reference

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report

21 January 2018

1 reference

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies

21 January 2018

1 reference

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct

21 January 2018

1 reference

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class

21 January 2018

1 reference

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

21 January 2018

1 reference

BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle

21 January 2018

1 reference

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgki

21 January 2018

1 reference

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

21 January 2018

1 reference

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

21 January 2018

1 reference

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.

21 January 2018

1 reference

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

21 January 2018

1 reference

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

21 January 2018

1 reference

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox

21 January 2018

1 reference

Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma

21 January 2018

1 reference

Novel therapeutic approaches for acute lymphoblastic leukemia

21 January 2018

1 reference

Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity

21 January 2018

1 reference

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

21 January 2018

1 reference

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

21 January 2018

1 reference

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

21 January 2018

1 reference

The treatment of acute lymphoblastic leukaemia in the elderly.

21 January 2018

1 reference

CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms

21 January 2018

1 reference

Investigational antibody-drug conjugates for hematological malignancies

21 January 2018

1 reference

Antibody therapy for acute lymphoblastic leukemia

21 January 2018

1 reference

Novel targeted therapies in acute lymphoblastic leukemia

21 January 2018

1 reference

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study

21 January 2018

1 reference

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

21 January 2018

1 reference

A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

21 January 2018

1 reference

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

21 January 2018

1 reference

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

21 January 2018

1 reference

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia

21 January 2018

1 reference

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

21 January 2018

1 reference

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

21 January 2018

1 reference

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

21 January 2018

1 reference

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

21 January 2018

1 reference

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

21 January 2018

1 reference

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.13205

1 reference

release_iisnyegpzjcv7dv5r7l45afyca

1 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iisnyegpzjcv7dv5r7l45afyca

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference